{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-003940","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.677514+00:00","generated_at":"2026-06-04T07:59:21.339748+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gain Therapeutics reports FY2023 net loss of $22.3M; cash runway into Q1 2025","bullets":["Net loss for FY2023 was $22.3M ($1.71 per share), vs $17.6M ($1.48) in FY2022.","R&D expenses rose to $11.5M from $8.4M due to Phase 1 trial of GT-02287 for GBA1 Parkinson's disease.","Cash and marketable securities $16.8M as of Dec 31, 2023; expected to fund operations into Q1 2025.","Initiated MAD part of Phase 1 trial of GT-02287; data presented at AD/PD 2024 and WORLD Symposium.","Raised $10.1M gross proceeds from public offering and private placement in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-003940","json":"https://secwatch.observer/filing/0001558370-24-003940.json","markdown":"https://secwatch.observer/filing/0001558370-24-003940.md","text":"https://secwatch.observer/filing/0001558370-24-003940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000155837024003940/0001558370-24-003940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000155837024003940/ganx-20240326x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:59:21.339748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fc1485618330f82be644d4512f177c7de1f44992","claim":"Gain Therapeutics, Inc. reported the year ended December 31, 2023 results: net income $22.3 million, EPS $1.71.","evidence_excerpt":"Net loss for the year ended December 31, 2023 was $22.3 million, compared to a net loss of $17.6 million for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000155837024003940/0001558370-24-003940-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$22.3 million"},{"label":"EPS","value":"$1.71"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}